Last reviewed 2026-05-21 · How we verify

Clozic (CLOBUZARIT)

Phase 2 active Small molecule ✓ Verified May 2026

Clozic (generic name: CLOBUZARIT) is a clobuzarit drug. It is currently in Phase 2 development.

Clobuzarit is thought to work by modulating a specific biological pathway, although the exact details of its mechanism are not yet fully understood.

Clozic is a small molecule with the synonyms CLOBUZARIT, ICI 55,897, and ICI-55897.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CLOBUZARIT
Drug class	clobuzarit
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have a complex communication system. Clobuzarit is believed to affect this system by influencing the way cells talk to each other, potentially leading to changes in how the body responds to certain conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Clozic CI brief — competitive landscape report
Clozic updates RSS · CI watch RSS

Frequently asked questions about Clozic

What is Clozic?

Clozic (CLOBUZARIT) is a clobuzarit drug.

How does Clozic work?

Clobuzarit is thought to work by modulating a specific biological pathway, although the exact details of its mechanism are not yet fully understood.

What is the generic name of Clozic?

CLOBUZARIT is the generic (nonproprietary) name of Clozic.

What drug class is Clozic in?

Clozic belongs to the clobuzarit class. See all clobuzarit drugs at /class/clobuzarit.

What development phase is Clozic in?

Clozic is in Phase 2.

Drug class: All clobuzarit drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing